Fierce Pharma

MAY 1, 2024

Following the lead of Eli Lilly, Pfizer will establish a direct-to-consumer service, selling some of its medicines online and avoiding industry middlemen. | Following the lead of Eli Lilly, Pfizer will establish a direct-to-consumer service, selling some of its medicines online and avoiding industry middlemen. The company plans to sell products such as its COVID treatment Paxlovid and a migraine nasal spray in this way, it told the Financial Times.

Marketing 300

Marketing Sales Medicine Leads 300

MedCity News

MAY 1, 2024

Walmart’s decision to shutter its healthcare division reflects just how difficult it is to achieve profitability in the primary care and telehealth markets. Experts think retailers simply aren’t prepared to handle the bevy of challenges that come along with delivering healthcare — but could this news also be a sign of the system being broken? The post Healthcare Is a Frontier Not Even Walmart Could Conquer — And It’s Not Looking Great For Others Either appeared first on MedCity News.

Healthcare 138

Healthcare Healthcare Retail Marketing 138

Pharmaceutical Technology

MAY 1, 2024

AstraZeneca has maintained that while the vaccine may, in “very rare” cases, cause TTS, the casual mechanism for this effect remains unknown.

145

145

European Pharmaceutical Review

MAY 2, 2024

Interim results of an ongoing study published in The Lancet have reported that Beyfortus (nirsevimab) reduced respiratory syncytial virus (RSV) hospitalisations by 82 percent in infants under six months, compared to infants who received no RSV intervention. Sanofi noted that as a long-acting antibody, Beyfortus has been shown to provide rapid protection, helping to prevent lower respiratory tract disease caused by RSV without the immune system needing activation.

Manufacturing 122

Manufacturing Government Networking Pharmaceutical 122

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

APRIL 30, 2024

The U.S. Federal Trade Commission (FTC) is not done with its crackdown on what it views as improper listing of patents with the FDA. | The U.S. FTC is not done with its crackdown on what it views as improper listing of patents in the FDA Orange Book. After an initial round of challenge launched in November against more than 100 patents, the FTC is back targeting another 300-plus patent listings by eight pharma firms.

FDA 313

FDA Pharma 313

MedCity News

APRIL 30, 2024

Enlaza Therapeutics’ drugs form covalent bonds that lock the therapy onto its target. With cancer as its initial focus, the startup contends its approach could offer safety and efficacy advantages compared to currently available targeted therapies. The post J.P. Morgan Leads $100M Financing for Startup’s R&D of Covalent Biologic Drugs for Cancer appeared first on MedCity News.

Leads 123

Leads Safety Biopharma Pharma 123

European Pharmaceutical Review

MAY 2, 2024

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a policy paper on its strategic approach to artificial intelligence (AI). It summarises the MHRA’s view on the UK government’s white paper on AI regulation published in 2023. Following publication of this white paper, the government requested that the MHRA outline the steps the agency is working on in relation to its expectations.

Safety 115

Safety Medicine Government Medical 115

Fierce Pharma

MAY 1, 2024

Just about two months into his CEO job at Emergent BioSolutions, Joseph Papa has laid out his turnaround plan for the CDMO-turned-biopharma company. | Merely about two months into his CEO job at Emergent BioSolutions, Joseph Papa has laid out his turnaround plan for the CDMO-turned-biopharma company. And it involves a major organizational restructuring.

Biopharma 308

Biopharma 308

MedCity News

MAY 3, 2024

Hospitals’ operating margins and patient volumes dropped slightly in March. While hospitals were doing relatively well financially during the first quarter of the year, this new data could suggest more financial challenges ahead for hospitals. But right now, it’s unclear whether the recent declines in hospitals’ margins and volumes will be short- or long-term.

Patients 122

Patients 122

PharmaVoice

MAY 1, 2024

The FDA’s newly launched Center for Clinical Trial Innovation potentially opens the door for more efficient and expanded AI use, but leaves pharmas wanting more guidance.

Pharma 115

Pharma FDA 115

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

Pharmaceutical Technology

APRIL 28, 2024

Artificial intelligence tools can be used for infection control through facial recognition systems designed to identify proper face mask use within hospitals.

119

119

Fierce Pharma

APRIL 29, 2024

The price tag includes both the approved cancer drug Qinlock and another Deciphera candidate heading to the FDA’s desk in the coming months.

335

335

MedCity News

APRIL 28, 2024

Optum is shutting down its virtual care unit after a three-year run. Industry experts agree that the closure reflects broader trends in the telehealth market, in which saturation and differentiation challenges are leading some providers to struggle. The post Experts Aren’t Surprised About Optum Closing Its Virtual Care Business appeared first on MedCity News.

Leads 126

Leads Marketing 126

pharmaphorum

MAY 3, 2024

Walgreens’ plans to disrupt the clinical trials sector have taken a step forward with a high-profile partnership with Boehringer Ingelheim

127

127

Advertisement

Pharmaceutical Technology

MAY 2, 2024

From Merck & Co to Sanofi, Pharmaceutical Technology lists the leading pharmaceutical companies spending the most on R&D in 2023.

Pharmaceutical 124

Pharmaceutical Leads 124

Fierce Pharma

APRIL 30, 2024

Biopharma companies and industry lobbying groups are striking out in their legal efforts to challenge price-cutting measures in the Inflation Reduction Act. | A federal judge tossed lawsuits by Bristol Myers Squibb and Johnson & Johnson, which questioned the constitutionality of the U.S. government requiring drugmakers to negotiate with Medicare on drug pricing.

Biopharma 307

Biopharma Government 307

MedCity News

MAY 2, 2024

Mariana Oncology brings Novartis a lead radiopharmaceutical program in development for small cell lung cancer. The deal is the latest in a string of big pharma M&A moves in the red-hot radiopharmaceuticals space. The post Novartis Extends Its Reach in Radiopharmaceuticals With $1B Mariana Oncology Acquisition appeared first on MedCity News.

Pharma 122

Pharma Leads Biopharma 122

pharmaphorum

APRIL 30, 2024

For the last few years, Walmart has been promising to disrupt the US healthcare sector with a national network of clinics providing low-cost care and telehealth services. Now, it is reining back on those plans.

Healthcare 112

Healthcare Healthcare Networking 112

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

Pharmaceutical Commerce

APRIL 29, 2024

A one-on-one with Thermo Fisher’s Wilfredo Marin, who dives into the value of ultra-low temperature storage, the need for flexibility in the cold chain logistics space, and more.

105

105

Fierce Pharma

MAY 2, 2024

With Moderna’s COVID-19 sales on the backfoot following the switch to an endemic vaccine market, the Massachusetts-based biopharma is busy laying the groundwork for its next potential mRNA shot in | Moderna currently expects initial approvals of its RSV vaccine to start rolling in during the first half of 2024, the company said Thursday. In turn, the company is eyeing a potential U.S. launch in the fall, which would capitalize on its established commercial efforts in the seasonal COVID-19 immuni

Biopharma 271

Biopharma Sales Marketing 271

MedCity News

APRIL 30, 2024

The Drug Enforcement Agency’s decision to reclassify cannabis to a Schedule III drug could mark the first step in a long process to establish a new normal for medical cannabis care. The post Momentum is Building to Put Medical Cannabis into Mainstream Healthcare appeared first on MedCity News.

Medical 117

Medical Healthcare Healthcare 117

pharmaphorum

APRIL 29, 2024

A partnership between Huma Therapeutics and Merck KGaA to develop digital support tools for cancer patients has borne fruit with the launch of a bladder cancer app in the UK

Patients 111

Patients 111

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

European Pharmaceutical Review

MAY 2, 2024

Recent developments in the biologic therapies sector include the authorisation of Pyzchiva ® (biosimilar ustekinumab) by the European Commission, and promising 12-month data for Roche’s subcutaneous injection of OCREVUS ® (ocrelizumab) for relapsing or primary progressive multiple sclerosis. The biologics market is expected to continue its fast growth despite the slowdown in funding observed in the past year.

Medicine 105

Medicine Manufacturing Biopharma Engineering 105

Fierce Pharma

MAY 3, 2024

Shortly after Novo Holdings’ parent company elected to resubmit paperwork around the investment firm’s proposed $16.5 billion buyout of CDMO giant Catalent, the U.S. | Shortly after Novo Holdings’ parent company elected to resubmit paperwork around the investment firm’s proposed $16.5 billion buyout of CDMO giant Catalent, the U.S. Federal Trade Commission has teed up a further extension on the deal’s review period.

282

282

MedCity News

MAY 3, 2024

Amgen is confident its injectable obesity drug would have a differentiated profile compared to medications now on the market from Novo Nordisk and Eli Lilly and it’s now preparing for Phase 3 testing. But an oral obesity drug in Amgen’s pipeline will not advance beyond Phase 1. The post Amgen Puts Its Weight Behind Obesity Drug With Potential Edge Over Lilly, Novo Nordisk Meds appeared first on MedCity News.

Medical 118

Medical Marketing Biopharma Pharma 118

pharmaphorum

APRIL 29, 2024

Patients in the US with the ultra-rare disease WHIM syndrome now have their first approved treatment, after X4 Pharma’s Xolremdi was given a green light by the FDA. Oral CXCR4 antagonist Xolremdi (mavorixafor) can be used in patients aged 12 and over with WHIM (warts, hypogammaglobulinemia, infections, and myelokathexis) syndrome, a congenital immunodeficiency characterised by low neutrophil counts that affects fewer than 1,000 people in the US.

FDA 108

FDA Pharma Patients 108

Advertiser: ZoomInfo

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

Competition

European Pharmaceutical Review

MAY 1, 2024

By providing pharma companies with a real-life replicable model of a cloud-first manufacturing facility, we will drive forward the digital capability of pharma manufacturers” A new digital collaboration is set to take advantage of a manufacturing facility model featuring innovative technologies, accelerating how fast new medicines are made. The Centre for Process Innovation (CPI), academia, and the pharma industry will work together to develop the model which will harness artificial intell

Medicine 105

Medicine Manufacturing Pharma Government 105

Fierce Pharma

APRIL 29, 2024

For Novo Nordisk to gain approval in the United States for its groundbreaking Awiqli (insulin icodec), it will have to first pass muster with a panel of experts next month,

FDA 261

FDA 261

MedCity News

MAY 2, 2024

Kaiser Permanente is deploying Innovaccer’s healthcare AI platform and population health management tools to support better value-based care — starting with its Washington market and potentially expanding to new markets in the future. The post Kaiser Permanente Is Deploying Innovaccer’s Value-Based Care AI Across Washington appeared first on MedCity News.

Healthcare 114

Healthcare Healthcare Marketing Management 114

Pharmaceutical Technology

MAY 3, 2024

UK liquid biopsy company, Angle, has agreed a supplier agreement with AstraZeneca to develop a Parsotix-based Androgen Receptor (AR) assay for use in prostate cancer studies.

104

104

Advertisement

Distribution